• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Using Letrozole-Induced Frozen Embryo Transfer Cycles Reduce the Risk of Hypertensive Disorders in Women with PCOS?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Zhang et al. (AJOG, 2021) assessed the impact of letrozole (an aromatase inhibitor) during frozen embryo transfer (FET) on obstetrical and perinatal outcomes of singleton and twin pregnancies compared with artificial cycle FET among women with polycystic ovary syndrome

METHODS:

  • Retrospective cohort study
  • Participants
    • Women with PCOS undergoing FET from 2010 to 2018
  • Exposure
    • Letrozole-stimulated cycle FET
    • Artificial cycle FET (estrogen and progesterone are used to mimic the natural cycle)
  • Study design
    • Multivariable logistic regression analysis was performed with control for potential confounders
  • Primary outcome
    • Incidence of hypertensive disorders of pregnancy

RESULTS:

  • 2427 women with PCOS
    • Artificial cycles: 1168 women
    • Letrozole-stim cycles: 1259
      • Letrozole alone: 25%
      • Letrozole plus gonadotropins: 75%
  • There was no significant difference between the groups for the following
    • Gestational diabetes
    • Abnormal placentation
    • Preterm premature rupture of membranes
  • Prevalence of the following birth outcomes were similar between groups
    • Preterm birth
    • Perinatal death
    • Birthweight outcomes
  • Singleton pregnancies resulting from letrozole-stimulated cycles had a lower risk of hypertensive disorder of pregnancy than those conceived by artificial cycle
    • Adjusted odds ratio (aOR) 0.63 (95% CI, 0.40 to 0.98)
  • There was also a decreased risk of hypertensive disorders of pregnancy in women with twin pregnancies resulting from letrozole-stimulated cycles, compared to those from artificial cycles
    • aOR 0.52 (95% CI, 0.30 to 0.87)
  • The cesarean delivery rate was significantly lower for singletons but not for twins in the letrozole group compared with pregnancies from the artificial cycle group
    • Singletons: aOR 0.63 (95% CI, 0.50 to 0.78)
    • Twins: aOR 1.20 (95% CI, 0.65 to 2.23)

CONCLUSION:

  • It is postulated that pregnancies conceived using artificial cycle FET do not have a corpus luteum and this may contribute to a higher incidence of hypertensive disorders of pregnancy
  • Incorporating letrozole into frozen embryo transfer (FET) protocols would lead to the development of a corpus luteum and therefore reduce the risk for hypertensive disorders of pregnancy in patients with PCOS
  • For women with PCOS undergoing FET, the use of letrozole for endometrial preparation was associated with fewer hypertensive disorders of pregnancy, compared with women who underwent artificial cycle FET
  • The authors conclude

Our findings provided a foundation that the increased risk of hypertensive disorder of pregnancy associated with frozen embryo transfer might be mitigated by utilizing physiological endometrial preparation protocols that lead to the development of a corpus luteum, such as a mild ovarian stimulation cycle for oligo- or anovulatory women

Learn More – Primary Sources:

Letrozole-induced frozen embryo transfer cycles are associated with a lower risk of hypertensive disorders of pregnancy among women with polycystic ovary syndrome

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does Endometrial Scratching Improve IVF Outcomes?
Are Adverse Birth Outcomes Following Medically Assisted Reproduction a Result of Treatment or Underlying Issues?
Cochrane Review: Letrozole vs Clomiphene Citrate for the Treatment of infertility in Women with PCOS

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site